Abstract
Soluble forms of CD83, a dendritic cell-specific surface glycoprotein, have been strongly proposed to be of therapeutic utility in inflammatory conditions such as multiple sclerosis and transplantation. We demonstrate here, however, that eukaryotically expressed, recombinant soluble human CD83-Ig molecules fail to achieve efficacy in model systems for those conditions: mouse experimental autoimmune encephalomyelitis models in vivo or in mixed lymphocyte reactions in vitro. These results raise concern as to the viability of a eukaryotically expressed soluble CD83 strategy for clinical therapeutic use.
MeSH terms
-
Animals
-
Antigens, CD / blood
-
Antigens, CD / immunology*
-
Antigens, CD / therapeutic use*
-
CD83 Antigen
-
Dendritic Cells / immunology
-
Encephalomyelitis, Autoimmune, Experimental / drug therapy*
-
Encephalomyelitis, Autoimmune, Experimental / immunology
-
Encephalomyelitis, Autoimmune, Experimental / metabolism
-
Humans
-
Immunoglobulins / blood
-
Immunoglobulins / immunology*
-
Immunoglobulins / therapeutic use*
-
Lymphocyte Culture Test, Mixed*
-
Membrane Glycoproteins / blood
-
Membrane Glycoproteins / immunology*
-
Membrane Glycoproteins / therapeutic use*
-
Mice
-
Mice, Inbred C57BL
-
Recombinant Fusion Proteins / immunology
-
Recombinant Fusion Proteins / therapeutic use
Substances
-
Antigens, CD
-
Immunoglobulins
-
Membrane Glycoproteins
-
Recombinant Fusion Proteins